Preclinical experiments demonstrated that PIT, when combined with programmed cell death protein 1 (PD-1) inhibition, amplified antitumor effects by initiating tumor cell death, which in turn activated dendritic cells. The gene discussed is PDCD1; the disease is neoplasm.